Results 71 to 80 of about 38,526 (184)

Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.

open access: yesPLoS ONE, 2013
CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on bortezomib-regulated cellular pathways. In the present study, we investigated CK2 expression in multiple myeloma and mantle cell lymphoma, two bortezomib ...
Sabrina Manni   +16 more
doaj   +1 more source

Cutaneous Crystal‐Storing Histiocytosis With Marginal Zone Lymphoma. A Case Report With A Striking Clinic Presentation

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Cutaneous crystal‐storing histiocytosis (CSH) is an extremely rare histopathologic finding of histiocytes accumulating crystals of immunoglobulin or paraproteins, often associated with lymphoplasmacytic malignancies. It commonly presents in a wide age range of both female and male adults with a history of a lymphoproliferative disorder ...
Ashton Arlen   +3 more
wiley   +1 more source

Spatial sequestration of activated-caspase 3 in aggresomes mediates resistance of neuroblastoma cell to bortezomib treatment

open access: yesScientific Reports
Neuroblastoma (NB) is the most common pediatric tumor and is currently treated by several types of therapies including chemotherapies, such as bortezomib treatment.
Kévin Berthenet   +13 more
doaj   +1 more source

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

open access: yesHaematologica, 2015
We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone ...
Maximilian Merz   +22 more
doaj   +1 more source

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Background Severe renal insufficiency requiring dialysis in newly diagnosed multiple myeloma (NDMM) patients has been independently associated with poor survival outcomes. However, there is a paucity of data on factors predicting renal recovery and survival outcomes of these patients.
Rintu Sharma   +13 more
wiley   +1 more source

Calcium Channel Blocker Verapamil Enhances Reticulum Stress and Death Induced by Proteasome Inhibition in Myeloma Cells

open access: yesNeoplasia: An International Journal for Oncology Research, 2010
The proteasome inhibitor bortezomib is clinically approved for the treatment of multiple myeloma. However, long-term remissions are difficult to achieve, and myeloma cells often develop secondary resistance to proteasome inhibitors.
Silke Meister   +6 more
doaj   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

open access: yesEuropean Journal of Haematology, EarlyView.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro   +12 more
wiley   +1 more source

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real‐World Evidence in a Rapidly Evolving Therapeutic Landscape

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
K. Mancuso   +18 more
wiley   +1 more source

Hypoxic and Fe‐Responses are Regulated by the ERFVII Factors and the PCO Branch of the N‐Degron Pathway According to Iron Availability

open access: yesPlant, Cell &Environment, EarlyView.
ABSTRACT In plants, iron homeostasis and oxygen metabolism are strictly related, indeed several Fe‐requiring enzymes catalyze reactions that also involve O2 as a reagent, product, entry or end point of the pathway. Oxygen sensing itself relies on the Fe‐dependent enzymes Plant cysteine oxidases.
Yuri Telara   +9 more
wiley   +1 more source

Detection of vascular amyloid deposits in a bone marrow aspirate

open access: yes
British Journal of Haematology, EarlyView.
Konstantinos Liapis   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy